BHCM
GPCR icon

Brevan Howard Capital Management’s Structure Therapeutics GPCR Stock Holding History

Brevan Howard Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2M Sell
47,266
-39,044
-45% -$2.67M 0.02% 525
2025
Q4 		$5.96M Buy
+86,310
New +$3.52M 0.07% 202

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Brevan Howard Capital Management's GPCR Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Structure Therapeutics (GPCR) stake by 45% in Q1 2026, selling an estimated $2.67M and leaving 47,266 shares worth $2.2M. The position accounts for 0.02% of the portfolio, ranked #525.

Brevan Howard Capital Management first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.96M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Brevan Howard Capital Management held 47,266 shares of Structure Therapeutics worth $2.2M as of Q1 2026.
  • Brevan Howard Capital Management sold 39,044 Structure Therapeutics shares in Q1 2026, an estimated $2.67M.
  • Structure Therapeutics made up 0.02% of Brevan Howard Capital Management's portfolio in Q1 2026, its #525 holding.
  • Brevan Howard Capital Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Structure Therapeutics position peaked at $5.96M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.